Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

@inproceedings{Feldman2010EfficacyAS,
  title={Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study},
  author={Gregory J. Feldman and Thomas M. Siler and Niyati Prasad and Damon Jack and Simon Piggott and Roger Owen and Mark T Higgins and Benjamin Kramer},
  booktitle={BMC pulmonary medicine},
  year={2010}
}
BACKGROUND Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting beta2-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD. METHODS Efficacy variables included 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week 12 (primary endpoint) and after Day 1, and the percentage of COPD days with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD)

  • SI Rennard, KR Chapman, +4 authors B Kramer
  • Chest 2009,
  • 2009
1 Excerpt

Safety and tolerability of single therapeutic and supratherapeutic doses of indacaterol in patients with chronic obstructive pulmonary disease (COPD)

  • SRC Pascoe, W Pleskow, S Perry, A Hmissi, L Brookman
  • Am J Respir Crit Care Med
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…